Table 1

Baseline demographics and clinical characteristics

Abatacept+MTX (N=104)
Mean age (SD), years56 (14)
Female, %84
Caucasian, %97
Mean disease duration (SD), years7 (9)
Mean tender joint count (SD)20 (12)
Mean swollen joint count (SD)13 (8)
Mean high-sensitivity CRP (SD), mg/dL1.4 (1.9)
Mean DAS28 (CRP)* (SD)5.3 (1.1)
Mean GLOESS† (MCPs 2–5) (SD)12.6 (4.1)
Mean dose of MTX, mg/week16
Concomitant corticosteroid use, %53
Concomitant NSAID use, %43
  • *n=103.

  • †n=96 (excludes patients from one site that experienced technical and quality issues with PDUS scoring and compliance issues).

  • CRP, C reactive protein; DAS, Disease Activity Score; GLOESS, Global OMERACT–EULAR (Outcome Measures in Rheumatology–European League Against Rheumatism) Synovitis Score; MCP, metacarpophalangeal joint; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PDUS, power Doppler and greyscale ultrasound.